This documents the first link between levels of E2F3 and paclitaxel in NSCLC, though a relationship between high levels of E2F3 activity and increased sensitivity to paclitaxel has been previously observed in ovarian [23] and ER-negative breast cancer [24]. This evidence concerns the gene E2F3 and non-small cell lung carcinoma.